Catch up on all H3 news and developments regarding research, ongoing trials and personnel.
In the News
Scrip
Scrip Asks…What Does 2022 Hold For Biopharma? Part 5: Clinical Trials
The COVID-19 pandemic drove huge shifts in clinical trial practice and the transformation is expected to continue even after the… Read More
Fierce Biotech
Chutes & Ladders
Eisai's cancer genomics drug discovery subsidiary, H3 Biomedicine, promoted Ping Zhu, Ph.D., to president and chief scientific officer, and Ross… Read More
NJBIZ
Eisai subsidiary appoints new leadership
H3 Biomedicine, a cancer genomics-based drug discovery subsidiary company of Woodcliff Lake pharmaceutical company Eisai, appointed a new executive leadership… Read More
Bio-IT World
H3’s Data Centric Approach to Cancer Genomics
Lihua Yu began her training as a biomedical engineer during her undergraduate studies, but for her Ph.D. training, she chose… Read More
Scrip
Scrip Asks…What Does 2021 Hold For Biopharma? Part 1: Tackling COVID-19
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key… Read More
BioPharm Insight
H3 Biomedicine in active discussions for co-developing its cancer genomics programs – CEO
H3 Biomedicine is in talks with pharma companies to co-develop one or more of its Phase I drugs that are… Read More
Boston Business Journal
H3 Biomedicine to Begin Trials of First-Ever Gene-Splicing Cancer Drug
Kendall Square-based cancer biotech H3 Biomedicine, created five years ago by Japanese drug firm Eisai, will bring its first drug… Read More
PharmaVOICE
H3 Biomedicine’s Dr. Lihua Yu Honored in PharmaVOICE 100
In her position as VP, data science and information technology, at H3 Biomedicine, Lihua Yu, Ph.D., is driving the expanded… Read More
Boston Business Journal
Foundation Medicine, H3 Biomedicine Partner to Develop Cancer Drugs
A partnership announced today between two Cambridge companies, Foundation Medicine (Nasdaq: FMI) and H3 Biomedicine, is further evidence of the… Read More
FasterCures
Fixes in Financing
High-risk, long-term investments are needed to turn medical innovations into lifesaving therapies. At FasterCures, we examine and highlight innovative funding mechanisms… Read More
European Business Review
Personal Medicine
Biomarker research is fundamental to the delivery of targeted therapeutics. An industry shift towards a more collaborative approach to patient-derived… Read More
Company
Information
H3 Biomedicine was founded in 2011 as a research and development engine focused on advancing drugs from bench to bedside.
For all media interested in speaking to members of H3 Biomedicine’s team, or receiving further information about the company or pipeline, please contact us.